Lupin Ltd is involved in the business of manufacturing pharmaceuticals. The company was founded in 1968. Lupin Laboratories Pvt. Ltd. was incorporated in 1972. It commissioned the first formulations plant and R&D Centre at Aurangabad in 1979. Lupin received US FDA approvals for the Ankleshwar and Mandideep plants in 1989. The company was listed on an exchange in 1993 after an IPO._x000D_ _x000D_ In 2000, the company received US FDA approval for the Cefotaxime facility at Mandideep. Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd., and as a result, Lupin Ltd was formed in 2001. After 2 years (2003), it incorporated Lupin Pharmaceuticals Inc. USA for trading, marketing and developmental activities in the US._x000D_ _x000D_ In 2007, the company acquired Rubamin Laboratories Ltd., Vadodara and renamed it Novodigm Ltd. It became the 5th largest generic player in the US in 2010. Post 2 years, the company entered the NIFTY 50 Index in 2012. The company finished the acquisition of Symbiomix Therapeutics, LLC, New Jersey, U.S., in 2017. It launched Atharv Ability – State-of-the-Art, Multi-Disciplinary Neuro Rehabilitation Center in Mumbai in 2023._x000D_ _x000D_ Lupin’s Supply Chain Team won the award for ‘Best-in-Class Supply Chain Strategy’ at the 15th ELSC Leadership Awards in 2023._x000D_

Business Segments

_x000D_

_x000D_
• Key Therapeutic Areas: The company offers an expansive portfolio of products under this segment. Through this segment, it enjoys a  substantial market share in therapies such as cardiovascular, respiratory, diabetes, neurology, gastrointestinal and women’s health.
_x000D_
• Generics: The company’s generic business is ranked #6 in the Indian Pharmaceutical Market (IPM). It possesses a significant presence in CNS, gynaecology, pain management and vitamin-mineral supplements, among others.  
_x000D_
• Biosimilars: The company runs this segment through Lupin Biotech, which manufactures high-quality biologics that are accessible and affordable for patients globally. Products under this segment include Filgrastim and Peg-Filgrastim, and Etanercept.
_x000D_
• Specialty: The specialty business of the company is supported by strong research and manufacturing capabilities. The specialty products under this segment include Solosec in the US and NaMuscla in Europe.
_x000D_
• Over-the-Counter (OTC): Under this segment, the company produces drugs, which are considered the first line of defence against non-serious ailments. A few of the products under this segment include LupinLife, Softovac, Lupizyme, etc.
_x000D_
• Active Pharmaceutical Ingredients (API): The company is a leading API manufacturer in India. It supplies to more than 70 countries around the globe.
_x000D_
• Global Institutional Business (GIB): This segment provides high-quality, affordable, and reliable medicines to underserved communities, enabling a healthy and disease-free life. The company has evolved into a comprehensive solution for all anti-TB medications.
_x000D_
• Tech-Driven Offerings: The company provides tech-enabled products such as Bluetooth-enabled inhalation devices or an AI-driven chatbot to answer queries about key therapies.
_x000D_

_x000D_

Subsidiary

_x000D_ As of March 31, 2023, the company had 28 subsidiaries and a few of them are listed below:_x000D_

_x000D_
• Lupin Pharmaceuticals, Inc., USA: It is a wholly owned subsidiary of Lupin Ltd, which was incorporated on June 30, 2003. It manufactures, markets and/or distributes more than 181 drugs in the United States.
_x000D_
• Pharma Dynamics (Proprietary) Limited, South Africa: This is a wholly-owned subsidiary of the company, which is one of the largest generic medicine providers in South Africa.
_x000D_

_x000D_

Key Personnel

_x000D_ Nilesh D Gupta, Managing Director_x000D_ _x000D_ Nilesh D Gupta is currently the MD of Lupin. He joined the company in 2002 and is responsible for its research, supply chain, manufacturing, quality, and regulatory operations. Mr Gupta has been involved in developing and executing the company’s core strategy, which has helped it emerge as a global leader in the generics space and in India._x000D_

Management Outlook

_x000D_

_x000D_
• The company believes that its India business has a very positive outlook and is well poised to achieve sustainable growth. Lupin is actively working on various initiatives to enhance its performance, which include focusing on business imperatives, process improvement, and engaging with stakeholders such as doctors, patients, distribution channels, and consumers. 
_x000D_
• The company is in a decent position to achieve new milestones and contribute to a brighter future by leveraging its brand-building capabilities, enhanced manpower and robust portfolio of products and by targeting depth into specific therapeutic segments.
_x000D_